Growth differentiation factor 15 (Gdf-15) : A novel biomarker associated with poorer respiratory function in covid-19

Leticia Alserawan, Patricia Peñacoba, Sandra Orozco, Diego Castillo, Esther Ortiz, Laura Martinez-Martinez, Esther Moga, Pere Domingo, Ivan Castellvi, Candido Juarez, Anaís Mariscal

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

16 Cites (Scopus)

Resum

It is essential to find new biomarkers for severity stratification of patients with coronavirus disease (COVID-19). Growth differentiation factor 15 (GDF-15) is upregulated in pathological conditions that involve inflammation and/or oxidative stress. We determined circulating levels of GDF-15 and correlated them with clinical and laboratory parameters reflecting severity in 84 patients with COVID-19, finding that GDF-15 levels were higher in both patients than in 20 healthy controls and were higher in patients with poorer respiratory function. GDF-15 levels also correlated with interleukin-6, C-reactive protein, ferritin and D-dimer levels and with neutrophilia and lymphopenia. Of all the analysed biomarkers, GDF-15 showed the best area under the receiver operating characteristics curve in identifying patients with poor respiratory function. In conclusion, our data support GDF-15 as a biomarker associated with pulmonary impairment in COVID-19 and so can potentially be useful in stratifying COVID-19 cases by severity.
Idioma originalAnglès
RevistaDiagnostics
Volum11
Número11
DOIs
Estat de la publicacióPublicada - 2021

Fingerprint

Navegar pels temes de recerca de 'Growth differentiation factor 15 (Gdf-15) : A novel biomarker associated with poorer respiratory function in covid-19'. Junts formen un fingerprint únic.

Com citar-ho